14815-12-4

Basic information

• Product Name: AcetaMide, 2,2,2-trifluoro-N-(2-Methoxyphenyl)-
• Synonyms: AcetaMide, 2,2,2-trifluoro-N-(2-Methoxyphenyl)-
• CAS NO: 14815-12-4
• Molecular Formula: C₉H₈F₃NO₂
• Molecular Weight: 219.1605296
• Mol File: 14815-12-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 50-50.5 °C
• Boiling Point: 254.7°C at 760 mmHg
• Flash Point: 107.8°C
• Appearance: /
• Density: 1.345g/cm³
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: 1.496
• PKA: 9.42±0.70(Predicted)
• CAS DataBase Reference: AcetaMide, 2,2,2-trifluoro-N-(2-Methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: AcetaMide, 2,2,2-trifluoro-N-(2-Methoxyphenyl)-(14815-12-4)
• EPA Substance Registry System: AcetaMide, 2,2,2-trifluoro-N-(2-Methoxyphenyl)-(14815-12-4)

Safety Data

• Hazardous Substances Data: 14815-12-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H8F3NO2/c1-15-7-5-3-2-4-6(7)13-8(14)9(10,11)12/h2-5H,1H3,(H,13,14)

Upstream product

• 90-04-0 2-methoxy-phenylamine 
• 407-25-0 trifluoroacetic anhydride 
• 354-38-1 2,2,2-trifluoroacetamide 
• 529-28-2 4-iodoanisol 
• 464-05-1 pyridinium trifluroacetate 
• 183266-61-7 1-(trifluoroacetyl)benzotriazole 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 1228757-63-8 N-(2-methoxyphenyl)-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl) trifluoroacetimidate 
• 1228757-59-2 2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl N-(2-methoxyphenyl)-2,2,2-trifluoroacetimidate 
• 1184086-20-1 4-methoxy-3-(2,2,2-trifluoroacetamido)benzenesulfonyl chloride 
• 1335406-99-9 N-[5-(5-bromo-2-methoxybenzenesulfonyl)-2-methoxyphenyl]-2,2,2-trifluoroacetamide 
• 1335407-01-6 5-(5-bromo-2-methoxybenzenesulfonyl)-2-methoxyaniline 
• 1335407-03-8 N-[5-(5-bromo-2-methoxybenzenesulfonyl)-2-methoxyphenyl]-N-(1-methylpiperidin-4-yl)amine 
• 1335405-10-1 N-[5-(5-bromo-2-methoxybenzenesulfonyl)-2-methoxyphenyl]-N-(1-methylpiperidin-4-yl)amine hydrochloride 
• 56807-17-1 2-methoxy-5-(morpholin-4-ylsulfonyl)aniline 
• 112255-65-9 2-((2-methoxyphenyl)amino)acetohydrazide 
• 1401621-91-7 5-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-2-methoxyaniline 
• 143681-34-9 N-(o-Anisyl)-2,2,2-trifluoroacetimidoyl chloride 
• 562039-10-5 N-{5-[3-(1-acetyl-4-piperidinyl)propanoyl]-2-methoxyphenyl}-2,2,2-trifluoroacetamide 

Relevant articles and documents

A one-pot procedure for trifluoroacetylation of arylamines using trifluoroacetic acid as a trifluoroacetylating reagent

A convenient procedure for the preparation of aryl trifluoroacetamides from aryl amines is described that employs 2-4 M equiv of trifluoroacetic acid in refluxing xylene as a trifluoroacetylating agent. Addition of an amount of pyridine that is equimolar to the amount of trifluoroacetic acid present in the reaction mixture facilitates the trifluoroacetylation of rather basic arylamines.

A simple and efficient method for trifluoroacetylation of arylamines using trifluoroacetic acid and triphosgene

A simple and efficient one-pot procedure for trifluoroacetylation of arylamines using trifluoroacetic acid and triphosgene is reported. A mixed trifluoroacetic anhydride generated in situ reacts with a variety of arylamines to give the corresponding trifluroacetamides in high yields.

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS

The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable